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1. Introduction  
Acute retinal necrosis (ARN) is a fulminant necrotizing form of retinitis of viral origin. With-
out treatment, ARN leads to the irreversible blindness by destruction of the retina and the 
optic nerve. The clinical observation was first described under the term Kirisawa uveitis 
(Urayama et al., 1971) while the term acute retinal necrosis was introduced by Young & Bird 
(1978). The international diagnostic standard criteria were defined by Holland et al. (1994). 
ARN is a rare disease occurring world-wide in approximately one per 1.5-2.0 million per-
sons per year (Muthiah et al., 2007; Vandercam et al., 2008). The rareness of this disease pre-
cludes randomized prospective clinical studies. Most observations are derived from small 
case series and homogenous international guidelines for therapy are still lacking. A few stu-
dies, however, allow statements on the causative agents and therapeutic principles. 
Initially, herpesvirus particles were detected by electron microscopy in the retina of enuclea-
ted eyes with ARN. The causative role of herpesviruses was further established by showing 
local virus-specific antibody production, by demonstrating viral nucleic acids with the poly-
merase chain reaction (PCR), and by therapeutic success with antiviral drugs (Culbertson & 
Atherton, 1993). The disease is mainly caused by the -herpesviruses varicella-zoster virus 
(VZV) or herpes-simplex virus (HSV) in 70% and 30% of the cases, respectively (e.g., 
Culbertson et al., 1986; Rummelt et al., 1992). While the -herpesvirus cytomegalovirus 
(CMV) plays a marginal role in the pathogenesis of ARN, the role of the -herpesvirus 
Epstein-Barr virus (EBV) remains controversial. Meta-analysis shows that men are affected 
slightly more frequently than women (Rautenberg et al., 2009). 
The early ARN diagnosis is primarily based on the virus-specific polymerase-chain reaction 
in punctuate fluid from the anterior chamber or the vitreous and can be supported by the 
detection of specific antibody titers from punctate fluid and serum using the Goldmann-
Witmer coefficient. Detection of virus DNA provides the basis for the early antiviral therapy 
which limits disease progression and risk for complications. Retinal infections by VZV or 
HSV are treated with aciclovir, valaciclovir, or famciclovir. Ganciclovir and valganciclovir 
are primarily used for the therapy of retinal CMV infections. In the case of resistance 
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development against antiviral drugs, foscarnet or cidofovir are available as second-line 
antiviral drugs. The early specific antiviral therapy is the crucial prerequisite for the optimal 
clinical outcome. The pros and cons of the different application routes (oral, intraveneous, 
intravitreal) are discussed in order to provide sufficient drug levels in the eye. The antiviral 
therapy of ARN must be combined with ophthalmological and surgical procedures. Early 
vitrectomy has been shown to lead to a significant reduction of secondary retinal 
detachment. The early and combined strategy is essential for the clinical outcome of the rare 
ARN (Hillenkamp et al., 2009a, b, 2010; Pleyer et al., 2009). 
2. Pathogenesis, epidemiology, and clinical course of ARN 
2.1 Viral pathogenesis 
The establishment of latency after primary infection is a common feature of herpesviruses. 
During latency, the entire, mostly inactive virus genome is maintained in the nuclei of host 
cells. The -herpesviruses VZV, HSV-1, and HSV-2 are characterized by their tropism for 
sensory neurones and epithelia. Via mucosal or cutaneous entry sites, the neurotropic her-
pesviruses gain access to the peripheral endings of sensory neurones. After virus uptake and 
axonal transport of the nucleocapsids, the virus establishes latency within approximately 14 
days in the nucleus of autonomous or sensory ganglia. The viral genome persists there in 
circular, extrachromosomal form (Steiner et al., 2007). 
In case of HSV, production of latency-associated viral transcripts seems to block virus repli-
cation and neuronal cell death. HSV-1 was shown to induce a local, CD8+ T cell-mediated, 
non-lytical inflammation in human trigeminal ganglia (Mott et al., 2009; Theil et al., 2003). 
These CD8+ T cells seem to block HSV reactivation via release of granzyme B which selecti-
vely degrades one of the regulatory proteins of HSV-1 and inhibits  reactivation already in 
the very early phase (Khanna et al., 2004; Knickelbein et al., 2008). Thus, a well balanced 
equilibrium between host defense and viral immune evasion mechanisms is formed during 
herpesviral latency. Since virus particles are not produced during latency, virus elimination 
by antiviral drugs is not feasible. 
The factors are not well defined which induce the reactivation of herpesvirus replication and 
the axonal transport of the viral nucleocapsids from the ganglion to the periphery. For HSV, 
ultraviolet light, neurosurgical procedures, periocular trauma and high-dosed steroid medi-
cation are known to cause reactiviation. During peripheral virus replication, clinical sym-
ptoms are observed in the region innervated by the respective sensory nerve, mostly in the 
form of oroacial herpes or as herpes zoster (shingles) and by far more rarely as ocular herpes 
(Liesegang, 2001; Lorette et al., 2006; Malvy et al., 2007). 
The extremely low incidence of the ocular herpes manifestations can be explained through 
epidemiology as well as neuroanatomy. HSV-1 and HSV-2 have strongly different capabili-
ties of establishing latency in trigeminal or sacral sensory ganglia and of inducing reactiva-
tion. Whereas 41% of the cases with latent trigeminal HSV-1 reactivate the virus, this occurs 
only in 4% of the trigeminal HSV-2 infections. In latent sacral HSV-2 infections, 89% of the 
patients develop recurrent genital herpes, in contrast to 25% of the cases with sacral HSV-1 
latency (Lafferty et al., 1987). The rate for the symptomatic recurrence of orofacial HSV-1 is 
0.12 per month in contrast to 0.001 for orofacial HSV-2 (Lafferty et al., 1987). The different 
rates of reactivation from different anatomical regions correspond to the mRNA prevalence 
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as detected by by PCR in trigeminal ganglia, 79% for VZV, 53% for HSV-1, and 7% for HSV-
2, respectively (Pevenstein et al., 1999). Moreover, the HSV-specific latency-associated trans-
cripts and HSV-reactive CD8+ T cells were clearly less frequent in the neurones projecting to 
the ophthalmic nerve as in the other branches of the trigeminal nerve (Hüfner et al., 2009). 
These findings indicate that HSV reactivations occur more rarely in the eye than in the other 
orofacial regions. 
As the latency site of CMV, hematopoetic myelomonocytic progenitor cells are considered, 
from which systemic dissemination occurs via monocytes (Crough et al., 2009; Sinclair, 2008; 
Sinclair & Sissons, 2006). EBV replicates primarily in the pharyngeal and tonsillar epitheli-
um and in B cells. EBV latency is localized to quiescent B lymphocytes (Miyashita et al., 
1995). Both viruses can be reactivated spontaneously or, drastically more frequently, during 
immunosuppression. Correspondingly, the simultaneous demonstration of DNA of differ-
rent herpesviruses is possible in retinitis or ARN (Hasselbach et al., 2008; Hillenkamp et al., 
2009a; Lau et al., 2007; Sugita et al., 2008). 
The mechanisms are not yet sufficiently clarified which lead to the viral infection of the 
retina and finally to ARN. In a murine model, retinitis of the contralateral eye was observed 
within three days after intravitreal inoculation with a highly neurovirulent HSV-1 strain 
(Labetoulle et al., 2000). The time course of virus spread and immunohistological findings 
support the theory of non-synaptic virus transfer between neurones and glia cells in the 
chiasma opticum leading to the infection of the contralateral eye (Labetoulle et al., 2000). 
This is clinically relevant, since specific antiviral therapy reduces the risk for bilateral ARN 
(Palay et al., 1991).  
For rare diseases such as herpesviral encephalitis or ARN, causative immunological defects 
have been discussed. In one study, plasmacytoid dendritic cells from nine ARN patients 
were significantly fewer than in healthy controls, as well as interferon- production and 
CD8+ cell responses were clearly diminished. This could contribute to the impaired control 
of latent herpesvirus infections and subsequent development of ARN (Kittan et al., 2007). 
2.2 Epidemiology 
ARN is an extremely rare disease. Patients with endogenous uveitis had ARN in 1.3% (41 of 
3060; 95% confidence interval [CI]: 0.97-1.83%; Goto et al., 2007). During a prospective study in 
Great Britain over a period of 12 months, an ARN incidence of 0.5-0.6 per million was 
determined (Muthiah et al., 2007). Retrospective results were obtained for the Netherlands 
with a similar incidence of 1.1-1.6 per million (Vandercam et al., 2008). Approximately 55% of 
ARN patients are men (Fig. 1; Rautenberg et al., 2009: ratio men/women: 1.18; 95% CI: 1.06-
1.29). In contrast, only 37.7% of the patients with orofacial herpes are men (95% CI: 33-43%; 
Lorette et al., 2006), while HSV seroprevalence is identical in both genders (Malkin et al., 2002).  
More than 97% (95% CI: 96-99%) of all ARN cases are caused by the -herpesviruses VZV, 
HSV-1, and HSV-2. VZV is the most common causative agent of ARN in approximately 70% 
(Fig. 2; Rautenberg et al., 2009; 95% CI: 66-76%) of ARN cases, followed by HSV-2 and HSV-
1. The age of ARN manifestation depends on the causative agent. Patients with VZV-
induced ARN were 48.8±19.6 years old (mean ±1 standard deviation; Fig. 3). The mean age 
of HSV-1- or HSV-2-induced ARN patients was 31.1±17.5 or was 47.8+-19.2 or 31.1+-17.5 
years, respectively 
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Fig. 1. Gender distribution in ARN patients. The total value (diamond) indicates slightly 
more men than women (54% men vs. 46% women). 
 
Fig. 2. Fraction of patients with VZV-induced ARN. The total value (diamond) indicates a 
favourite role of VZV (about 70%) in this rare disease.  
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(Ganatra et al., 2000; Itoh et al., 2000; Kychenthal et al., 2001; Rahhal et al., 1996; 
Schlingemann et al., 1996; Tran et al., 2003b; van Gelder et al., 2001). According to these 
results, a cut-off value of 36 years allows to discriminate HSV-2 from the other herpesvius-
induced ARN (Fig. 3; sensitivity: 64%; specificity: 83%; positive predictive value at 30% 
prevalence: 56%; negative predictive value at 30% prevalence: 84%). The diagnostic 
discrimination between ARN caused by HSV-1, HSV-2, or VZV is not highly relevant, since 
the therapy is identical in these cases, primarily by aciclovir.   
In contrast, the virological and clinical discrimination of CMV retinitis from ARN caused by 
the three -herpesviruses is very important, since the drug of choice is ganciclovir in CMV 
infections. CMV as the causative agent of a viral retinitis in absence of immunsuppressive 
therapy in immunocompetent patients is extremely rare. To our knowledge, only four such 
cases were documented in the literature (Silverstein et al., 1997; Tajunisah et al., 2009; Ura-
yama et al., 1971; Voros et al., 2006). 
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Fig. 3. Age-distribution of patients who contracted ARN by different herpesviruses. Analy-
sis showed a significant younger age in patients who were infected by HSV-2 as compared 
to the other herpesviruses. The triangle within the box indicates the mean. 
The controversial role of EBV for ARN was investigated in a case control study (Ongkosu-
wito et al., 1998). By qualitative PCR, EBV was detected in one out of 24 ocular ARN sam-
ples. However, three of 46 vitreous samples from a control group also contained EBV DNA 
(odds ratio: 0.62; 95% CI: 0.06-6.34). Therefore, an association between the demonstration of 
EBV DNA and ARN could not be determined. Only a few studies analysed EBV DNA 
prevalence in ARN (Abe et al., 1996; Hillenkamp et al., 2009a; Itoh et al., 2000; Lau et al., 
2007; Ongkosuwito et al., 1998; Sugita et al., 2008; Tran et al., 2003a; Yamamoto et al., 2008). 
In nine of 134 ARN patients, EBV DNA was detected from ocular samples. In seven of these 
nine ARN patients (78%; 95% CI: 40-96%) VZV DNA was detected in addition to EBV by 
PCR (Hillenkamp et al., 2009a; Lau et al., 2007; Sugita et al., 2008). In theory, quantitative 
PCR methods could contribute to a clarification. However, there are no standard values for 
clinically relevant DNA concentrations in ocular materials and neither the diagnostic 
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samples nor the PCR methods are sufficiently standardized. In summary, EBV seems to play 
no or -if at all- only a minor role in ARN development. 
2.3 Clinical course 
Almost 90% of all ARN cases remain unilateral (Hillenkamp et al., 2009a; Muthiah et al., 
2007; Usui et al., 2008; Vandercam et al., 2008). In approximately 10% of the patients, also the 
contralateral eye is affected within one to six weeks, in an extreme case after up to 34 years 
(Falcone & Brockhurst, 1993; Saari et al., 1982; Schlingemann et al., 1996). A case-control 
study revealed that aciclovir therapy considerably reduces the risk for the contralateral eye 
(Palay et al., 1991). As soon as the ARN diagnosis is made, antiviral therapy should be 
started in order to avoid disease progression. Longer termed aciclovir prophylaxis should be 
considered (Cordero-Coma et al., 2007). 
An increased ARN risk was discovered for the HLA alleles DQw7, DR4, and Bw62 (odds 
ratio: 5.2 and 7.3 respectively; Holland et al., 1989). Moreover, there is a 20-fold increased 
risk (p=0.05) for a fulminant ARN course in the presense of the HLA DR9 allele (Matsuo & 
Matsuo, 1991). Several case reports describe ARN following HSV encephalitis (Bristow et al., 
2006; de la Blanchardiere et al., 2000; Gain et al., 2002; Ganatra et al., 2000; Gaynor et al., 
2001; Hadden & Berry, 2002; Kim & Yoon, 2002; Maertzdorf et al., 2001; Pavésio et al., 1997; 
Yamamoto et al., 2007). In a retrospective study, thirteen of 52 patients showed infectious or 
non-infectious neurological diseases in the medical history (Vandercam et al., 2008). Four of 
eleven patients had HSV encephalitis 20.6 months (mean) prior to ARN. Two of 28 patients 
had VZV encephalitis 28 months (mean) before. The HSV patients showed a unilateral ARN, 
whereas both immunosuppressed VZV patients developed bilateral ARN. Besides various 
case reports, these results clearly demonstrate herpes encephalitis as a risk factor for ARN 
which needs attention in neurology and ophthalmology. 
3. Virus diagnostics 
3.1 Preanalytical conditions 
Diagnostic samples can be generated in early stages by puncture of the anterior chamber, by 
paracentesis, by fine needle aspiration of vitreous fluid, or in advanced conditions by thera-
peutic pars plana vitrectomy (Winterhalter et al., 2007). The rapid PCR demonstration of 
virus DNA is highly important for the therapy, because specific antiviral drugs are used. 
Since herpesviruses and their DNA genomes are rather stable, the transport of fluid from 
the anterior chamber or from the vitreous does not need special precautions. Only in the 
case of prolonged transport times, the samples should be shipped in cooled conditions. The 
major diagnostic test is the PCR for herpesviral DNA for the direct demonstration of the 
causative agent. Virus-specific serologic tests can serve as indirect methods in order to show 
local antibody production at delayed time points. The major advantage of PCR testing is the 
low sample volume required and the independence of time-delayed immune reaction. Due 
to the rareness of ARN and to the critical contribution of antiviral therapy, the authors re-
commend the genotypic sensitivity test after demonstration of herpesvirus DNA. In case of 
failure of the antiviral therapy, this allows the rapid decision for either switching to cidofo-
vir or foscarnet or for increasing aciclovir dosage in case of preserved drug sensitivity. 
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3.2 Nucleic acid diagnostics 
The clinical ARN diagnosis needs the critical validation by virus-specific PCR. During the 
initial stage, only PCR allows rapid and valid results. Time-delayed PCR diagnostics lead to 
diminished test sensitivity (de Boer et al., 1996; Knox et al., 1998). Due to the high test sensi-
tivity of the PCR, 20-50 μl sample volume is sufficient in most cases. The PCR discrimination 
beween HSV-1 and HSV-2 is an established method. Real-time PCR methods allow the 
quantitation of viral loads in copy number per ml. Although there are no standards avai-
lable for a clinically relevant virus load value, the quantitation is relevant to discriminate 
between the major causative agent and an additional, perhaps weak reactivation of another 
herpesvirus, e. g., under immunosuppression (Hasselbach et al., 2008). 
3.3 Antibody assays 
The quantitative determination of antibody titers from the anterior chamber or the vitreous 
in comparison to the serum levels is an indirect and supporting procedure for virus-specific 
diagnostics at delayed time points. For the determination of the Goldmann-Witmer coeffi-
cient (antibody index, AI; Goldmann & Witmer, 1954), the intraocular and serum antibody 
titers and total IgG values are included in the following formula: 
AI = (antibody titer punctate/antibody titer serum) / (total IgG punctate/total IgG serum) 
Most authors consider an AI > 2-3 an obvious indicator of intraocular antibody production 
(de Boer et al., 1994; Dussaix et al., 1987; Fekkar et al., 2008; Pepose et al., 1992). Serological 
procedures have the disadvantages that significant antibody levels can be expected only 
after one to two weeks and that a false-negative AI can result from massive disturbance of 
the blood-eye barrier. In the case of latently peristing herpesviruses, an ocular reactivation 
does not necessarily lead to a significant AI increase. Moreover, there are serological cross-
reactivites between HSV and VZV (Pepose et al., 1992). Finally, the intraocular antibody 
generation can be variable in immunosuppressed or HIV-infected patients (de Boer et al., 
1996; Doornenbal et al., 1996; Kijlstra et al., 1989, 1990). 
4. Therapy 
4.1 Drugs directed against -herpesviruses 
Aciclovir by the parenteral route is the drug of choice in severe, acute HSV or VZV infec-
tions. The acyclic guanosine derivate aciclovir is specifically activated by the viral enzyme 
thymidine kinase of HSV or VZV to its monophosphate. Ubiquitous cellular kinases are res-
ponsible for the conversion to aciclovir triphosphate which is a specific inhibitor for the viral 
DNA polymerase (de Clercq, 2004). The dosage is based on tissue culture-derived determi-
nations of the 50%-inhibitory concentration (IC50) of aciclovir against HSV-1, HSV-2, or 
VZV. Due to a lack of standardisation of the assay conditions and the test viruses, these 
values are variable, up to several orders of magnitude. The IC50 values were 0.02 to 13.5 
μg/ml for HSV-1, 0.01 to 9.9 μg/ml for HSV-2 and 0.12 to 10.8 μg/ml for VZV (O'Brien & 
Campoli-Richards, 1989). Due to the three hours half life of aciclovir, it should be administe-
red intraveneously at 10 mg/kg for ten to 14 days three times daily. Consecutively, the oral 
application of five times daily 800 mg for further six weeks is recommended (Blumenkranz 
et al., 1986; Duker & Blumenkranz, 1991; Morse & Mizoguchi, 1995; Palay et al., 1991). This 
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recommendation is based on a case-control study in which most of the bilateral ARN cases 
ocurred within a period of six weeks and in which 90% of the bilateral ARN cases could 
have been avoided by aciclovir therapy (Palay et al., 1991). After the start of the antiviral 
therapy, new lesions should not occur from the second day on. From the fourth or fifth day 
on, the retinal infiltrates should show a tendence for regression. After one month, a comple-
te remission should be achieved (Blumenkranz et al., 1986). If this is not accomplished, 
either there was an insufficient drug dosage, or antiviral resistance has developed which is 
more frequently seen in immunosuppressed patients. The side effects of aciclovir are rather 
weak and rare and may include mild serum creatinine increase, nausea, and vomiting. 
Presently, the authors recommend aciclovir as first-line therapy of choice in the early phase 
of the disease. This is based on the long-termed experience with this drug. Moreover, this 
excludes influences from the intra- and interindividual variability of the oral bioavailability 
of valaciclovir (Hillenkamp et al., 2009a, b, 2010; Phan et al., 2003). The management of ARN 
by antiviral drugs has been summarized in a recent review article (Tam eta al., 2010). 
Valaciclovir is the valyl ester of aciclovir, which is quickly taken up into enterocytes after 
oral administration via enteric aminoacid transport systems and which is then hydrolyzed 
to the active prodrug aciclovir (Granero & Amidon, 2006; Katragadda et al., 2005). The oral 
bioavailability of valaciclovir of 54% is three times higher than that of aciclovir (Soul-Law-
ton et al., 1995). When 1000 mg valaciclovir were administered three times daily, aciclovir 
serum levels of 4.41 μg/ml and aciclovir levels in the vitreous of 1.03 μg/ml were reached. 
These concentrations are in the IC50 range for most HSV or VZV isolates. The lower peak 
concentrations during oral in comparison to parenteral aciclovir therapy minimize the risk 
for renal side effects (Huynh et al., 2008).  
Famciclovir is an orally available di-acetyl derivate of penciclovir. By deacetylation, famcic-
lovir is metabolized in the liver to the active prodrug penciclovir which is secreted without 
modification by the kidneys (Chakrabarty et al., 2004). The oral bioavailability of famciclovir 
is 77% and, thus, approximately 1.5-fold higher than that of valaciclovir (Soul-Lawton et al., 
1995) or 3.4-fold higher than that of aciclovir (15–30%; Fletcher & Bean, 1985). By oral 
administration of 500 mg every eight hours, intravitreal penciclovir concentrations of 1.2 
μg/ml can be reached (Chong et al., 2009), which is appropriate for the therapy of non-
resistant HSV-1, HSV-2, or VZV strains. In some single case reports, famciclovir was active 
against aciclovir-resistant VZV strains (Figueroa et al., 1997). However, the main reasons for 
aciclovir resistance are mutations of the viral thymidine kinase gene, which would typically 
also result in penciclovir resistance. 
Based on case reports with orally available prodrugs of aciclovir (Emerson et al., 2006; 
Savant et al., 2004), a pilot study was performed with ten eyes of eight patients (Aizman et 
al., 2007). Under the oral therapy with 1 g valganciclovir or 500 mg famaciclovir three times 
daily, the ARN regression occurred within six days and the maximal improvement within 
17 days without any case of contralateral ARN during further 36 weeks of observation. As 
long as randomized prospective studies on the efficiency of the oral aciclovir alternatives are 
not yet available, the initial standard therapy should be performed with intraveneous 
aciclovir, only. 
Resistance mutations. Especially in immunosuppressed patients, resistance development 
against aciclovir is observed frequently. However, underdosage must be excluded first. 
Under optimal conditions, the genotypic viral resistance can be determined by DNA PCR 
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and sequencing of the viral gene for thymidine kinase and by the sequence comparison with 
known resistant viruses within a few days. The cultural resistance testing depends on the 
successful virus isolation. This procedure is slower, hardly standardized and only possible 
in a few reference laboratories. More than 90% of the resistance cases result from mutations 
of the thymidine kinase gene. In case of resistance, cidofovir and foscarnet are usually the 
only available alternatives, since their activity mechanism is independent of the viral thymi-
dine kinase. Both drugs can also be used for ganciclovir-resistant CMV strains. 
Cidofovir is an acyclic nucleosid phosphonate with a broad activity spectrum against DNA 
viruses (de Clercq & Holý, 2005). Host cell kinases convert cidofovir to the active diphos-
phonyl ester which acts as a competitive inhibitor of the viral DNA polymerases and indu-
ces viral DNA chain termination. Aciclovir-resistant virus strain may be susceptible to cido-
fovir. The drug is administered intraveneously since its oral bioavailability is only 5%. The 
peculiarity of cidofovir is its very high intracellular half-life time of more than 24 hours (de 
Clercq & Holý, 2005). Cidofovir should be used only as a drug of second choice. It is infused 
in a dose of 5 mg/kg over one hour once weekly in two weeks. For maintenance, the infu-
sion is then repeated every second week in the same dosage. The major disadvantage of 
cidofovir is its nephrotoxicity which is due to the accumulation of this drug by an anion 
transporter system of the proximal tubuli of the renal cortex (Ho et al., 2000). Since cidofovir 
is renally secreted, it must be combined with probenecid for kidney protection. 
Foscarnet. In the case of a proven resistance against aciclovir, ganciclovir, or their prodrugs, 
foscarnet is the drug of choice. Foscarnet is a pyrophosphate analogon which occupies the 
pyrophosphate binding site on the herpesviral DNA polymerase and inhibits the release of 
pyrophosphate from the terminal nucleotide triphosphate of the growing viral DNA chain 
(Biron, 2006). Due to the very low oral bioavailability of 20%, the drug is administered by 
large-volume intraveneous infusions. Foscarnet is used in a dosage of 60 mg/kg every eight 
hours. Foscarnet is renally eliminated without any metabolic modification. In patients with 
diminished renal function, the dosis must be adjusted to the creatinine clearance value. The 
major side effect of foscarnet is its nephrotoxicity.  
Intravitreal application. Vitreous concentrations of aciclovir following intravenous 
administration has not yet been tested on a broad basis. Therefore, in patients, who do not 
respond to intravenous therapy, the intravitreal application of the respective antiviral drug 
should be considered in order to rapidly achieve high concentrations of the drug and, thus, 
an improved prognosis (Hillenkamp et al., 2009a, 2010; Scott et al., 2002; Velez et al., 2001; 
Zambarakji et al., 2002). This strategy allows high intraocular drug levels under reduced 
systemic exposure. Studies on repeated injections are not yet available. 
4.2 Drugs directed against cytomegalovirus 
In contrast to the -herpesviruses, CMV lacks a viral thymidine kinase. Presently, four 
drugs are licensed for CMV therapy: ganciclovir, valganciclovir, cidofovir, and foscarnet. All 
of them target the viral DNA polymerase and inhibit the viral DNA synthesis. 
Ganciclovir and its orally available valyl ester-derivate valganciclovir are the drugs of first 
choice for the therapy of CMV-induced diseases (de Clercq, 2004). The substances are 
monophosphorylated in CMV-infected cells by the CMV-specific protein kinase UL97, and 
subsequently triphosphorylated by cellular kinases. The incorporation of the acyclic 
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ganciclovir triphosphate into the growing viral DNA chain results in the blockade of 
polymerase translocation (Reid et al., 1988). Since the oral bioavailability of ganiclovir is 
only approximately 5%, the drug should be administered intravenously during the 
ganciclovir disease. In most cases, 10 mg/kg i.v. daily should be sufficient for the CMV 
therapy in ARN cases. The oral bioavailability of valganciclovir is approximately 60%. A 
daily dose of 900 mg will yield serum concentrations comparable to 5 mg/kg intraveneous 
ganciclovir or a 1,7-fold serum concentration in comparison to 1000 mg oral ganciclovir 
(Cvetković & Wellington, 2005). The major side effect of systemic ganciclovir therapy is 
neutropenia in approximately 8% of the patients. Therefore, ganciclovir therapy needs the 
regular control of blood counts, as well as the surveillance of renal function (Paya et al., 
2004). 
UL97 resistance mutations. Mutations of the UL97 protein kinase of CMV are the major 
cause of resistance against ganciclovir and its derivates. The resistence is determined geno-
typically by sequencing if the viral genes for the UL97 kinase and for the DNA polymerase. 
The most frequent ganciclovir resistence mutations in UL97 (codons 460, 520, 590-607) inhi-
bit ganciclovir phosphorylation which is the prerequsite for antiviral activity (Chou et al., 
2008). The activity of cidofovir and foscarnet is independent of the protein kinase UL97 and 
appropriate for the therapy of many DNA viruses.  
4.3 Differential diagnosis 
During the early disease stages, additional infectious agents, rheumatological disorders, 
autoimmune uveitis, or intraocular lymphomas have to be considered (Table 1). Whereas  
 
Disease Diagnosis First-line therapy 
ARN by varicella zoster virus PCR aciclovir 
ARN by herpes simplex virus PCR aciclovir 
ARN by cytomegalovirus PCR ganciclovir 
ARN by Epstein-Barr virus PCR not available 
Progressive outer retina necrosis PCR, serology dependent on the agent 
Cytomegalovirus retinitis PCR ganciclovir 
Lyme borreliosis serology, PCR cephalosporin 
Syphilis serology penicillin 
Toxoplasmosis retinitis serology, PCR pyrimethamine/sulfonamide 
Tuberculosis culture, PCR antimycobacterial therapy 
Endogeneous endophthalmitis culture, PCR dependent on the agent 
Bacterial eye infection culture, PCR dependent on the agent 
Fungal eye infection culture, PCR, Antigen Candida: Fluconazol 
Aspergillus: Voriconazol 
Behçet’s disease clinic, pathergia test immunosuppression 
Sarcoidosis histology immunosuppression 
Idiopathic chorioretinitis exclusion diagnosis immunosuppression 
Idiopathic retinovasculitis exclusion diagnosis immunosuppression 
Intraocular lymphoma cytology, tumor genetics radiochemotherapy 
Table 1. Differential diagnosis of acute retinal necrosis. 
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the start of ARN therapy is critical for the outcome the initiation of the therapy for most 
alternative causes is by far less urgent. Due to the similar clinical appearance, toxoplasmosis 
chorioretinitis is an important differential diagnosis (Balansard et al., 2005; Hasselbach et al., 
2008; Moshfeghi et al., 2004). An ocular manifestation of syphilis can show many different 
symptoms and can mimick various diseases. In contrast to ARN, CMV retinitis shows weak 
inflammation signs in the anterior chamber and the vitreous. Patients with CMV retinitis are 
usually infected with human immunodeficiency virus (HIV) with less than 50 CD4+ T 
cells/μl. CMV retinitis is resistant to aciclovir therapy. Therefore, the early PCR test for 
virus DNA is necessary. 
Finally, progressive outer retina necrosis (PORN) forms another differential diagnosis, 
which was mainly described in HIV patients (Forster et al., 1990). Typically, the outer retinal 
layers are primarily affected multifocally, while the inner retinal layers are less concerned. 
In contrast to ARN, there is no vasculitis component. The course of PORN disease is extre-
mely rapid, spreading to the the deep retinal layers and leading to retinal detachment. Pa-
tients with PORN usually show coinfection with HIV and VZV. 
5. Conclusion 
ARN occurs in up to one per million persons per year. The virus-caused disease remains 
unilateral in approximately 90% of the cases. Without treatment, ARN shows poor progno-
sis. The immediate calculated antiviral therapy by aciclovir or its prodrugs is justified, since 
approximately 70% of the cases are caused by VZV and 30% by HSV. The causative role of 
EBV remains controversial; often, EBV reactivation occurs concomitantly with VZV reactiva-
tion. While EBV reactivation cannot be treated efficiently, aciclovir is appropriate for VZV 
and HSV reactivations. The very rare case of CMV in ARN is an indication for ganciclovir or 
its prodrug. The virus-specific DNA PCR test from fluid of the anterior chamber or the vitre-
ous provides the critical indication for the specific therapy. Disease progression and compli-
cations rates can be limited by additional immediate conservative and surgical therapy. 
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